Mechanisms and Therapeutic Advances in Cancer Metastasis: Cancer metastasis is a leading cause of cancer-related mortality, involving the spread of malignant cells from the primary tumor to distant organs, forming resistant secondary growths. This review examines the biological mechanisms of metastasis, which unfolds in key steps: invasion, circulation, colonization, and proliferation. Key processes, including epithelial-mesenchymal […]
Author Archives: truemeds
Mastering Metabolism: The mechanistic Target of Rapamycin (mTOR) is a central regulator of cellular metabolism, integrating nutrient, energy, and hormonal signals to control growth, protein synthesis, lipid metabolism, and autophagy. As research advances, mTOR has emerged not only as a master controller of metabolic health but also as a promising therapeutic target for aging and […]
Jasmonates are a vital class of plant hormones that regulate a wide range of physiological processes, from stress responses and immunity to growth and reproduction. Recent research has revealed that the effectiveness of jasmonates depends not only on their biosynthesis and perception but also on their precise intracellular and intercellular transport. This blog explores the […]
Vinpocetine is a synthetic derivative of the periwinkle plant alkaloid vincamine, widely recognized for its potential cognitive-enhancing and neuroprotective effects. Originally developed and prescribed in Europe and Asia for stroke recovery and age-related cognitive decline, vinpocetine has also gained popularity in the U.S. as a nootropic supplement—though it remains controversial due to safety concerns and […]
Epigenetics and Cancer Stem Cells are a rare but critical subpopulation of tumor cells that drive tumor initiation, metastasis, therapy resistance, and relapse. Recent research highlights the pivotal role of epigenetic mechanisms—including DNA methylation, histone modification, and chromatin remodeling—in sustaining CSC identity and function. These modifications not only regulate oncogenic pathways like Wnt, Hedgehog, and […]
KRAS has long been considered an elusive target in oncology due to its structural resistance to conventional drug design. However, recent breakthroughs—especially the discovery of the KRAS G12C mutation—have enabled the development of covalent inhibitors that lock the protein in its inactive GDP-bound state. The FDA approvals of Sotorasib and Adagrasib have transformed the treatment […]
KRAS mutations are among the most prevalent oncogenic drivers in solid tumors, yet they have long been considered undruggable. AMG 410 represents a new generation of KRAS inhibitors designed to overcome these challenges. Unlike covalent, mutation-specific agents, AMG 410 is a non-covalent, state-independent inhibitor capable of targeting multiple KRAS mutations, including G12D, G12V, and G13D. […]
Tyrosine kinases play a pivotal role in cellular signaling pathways that regulate proliferation, differentiation, metabolism, and apoptosis. In cancer, mutations, gene fusions, and autocrine signaling loops can lead to the aberrant activation of these kinases, resulting in unchecked tumor growth and survival. This blog explores the mechanisms behind tyrosine kinase–driven oncogenesis and highlights both established […]
Apoptosis, or programmed cell death, is a fundamental biological process that protects the body by eliminating damaged or dangerous cells. In cancer, this system is often disrupted, allowing malignant cells to evade death and thrive. This blog explores the critical role of the mitochondrial apoptotic pathway and the BCL-2 family of proteins in cancer development […]
Peficitinib hydrobromide, a potent pan-Janus kinase (JAK) inhibitor, has emerged as a valuable compound for pharmaceutical research and generic drug development. Initially approved in Japan for the treatment of rheumatoid arthritis, Peficitinib demonstrates strong clinical efficacy and a well-defined pharmacological profile. Its broad activity across JAK1, JAK2, JAK3, and Tyk2, along with excellent oral bioavailability […]